Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Chief Development Officer | January 28, 2021 | January 29, 2021 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Chief Development Officer | August 28, 2023 | August 29, 2023 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Chief Development Officer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Esperion Therapeutics, Inc.
Report date January 28, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,500 |
Reported balance
After 2021-01-28 transaction · row 1
1 source rowRow 1 · 2021-01-28 · Grant · Acquired 7,000 · Balance 22,500 F1: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.12 · Expires 2031-01-28 | Direct | 31,000 |
Reported balance
After 2021-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-28 · Grant · Acquired 31,000 · Balance 31,000 F1: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021.
OnKure Therapeutics, Inc.
Report date August 28, 2023 · Filed August 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,225 |
Reported balance
After 2023-08-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-28 · Exercise / conversion · Acquired 15,625 · Balance 55,225 F1: Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 39,600 |
Reported balance
After 2023-08-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-08-28 · Sale · Disposed 15,625 · Balance 39,600 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-12-08 | Direct | 109,375 |
Reported balance
After 2023-08-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-28 · Exercise / conversion · Disposed 15,625 · Balance 109,375 F3: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.
Structure Therapeutics Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 155,187 |
Reported balance
After 2026-03-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 47,706 · Balance 155,187 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.82 · Expires 2036-03-18 | Direct | 59,073 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 59,073 · Balance 59,073 F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.
F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
F4: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 16:30 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantEmployee Stock Option (right to buy) · Derivative | 59,073 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001801842-26-000003 · form4-03232026_040310.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,073 Underlying: Ordinary Shares · 59,073 shares Expires 2036-03-18 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 16:30 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantOrdinary Shares | 47,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001801842-26-000003 · form4-03232026_040310.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,187 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 18:20 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | Tax withholdingOrdinary Shares | 4,836 | $20.99 | $101,507.64 |
DisclosureSEC source: 0001801842-26-000002 · form4-03052026_060304.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,481 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| November 20, 2025 Filed Mar 5, 2026 18:20 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantAmerican Depositary Shares · Derivative | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001801842-26-000002 · form4-03052026_060304.xml · derivative · entry 3 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462 Underlying: Ordinary Shares · 711 shares Expires not disclosed F3 · derivative.exercise_price: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F5 · kind: Voluntary reporting of the acquisition of 237 ADSs by the Reporting Person on November 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan. F3 · derivative.exercise_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F3 · derivative.expiration_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 21:25 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | Tax withholdingOrdinary Shares | 6,021 | $7.74 | $46,622.41 |
DisclosureSEC source: 0001801842-25-000004 · form4-09222025_090903.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,317 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award. Read SEC document |
| May 20, 2025 Filed Mar 5, 2026 18:20 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantAmerican Depositary Shares · Derivative | 225 | $0.00 | $0.00 |
DisclosureSEC source: 0001801842-26-000002 · form4-03052026_060304.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225 Underlying: Ordinary Shares · 675 shares Expires not disclosed F3 · derivative.exercise_price: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F4 · kind: Voluntary reporting of the acquisition of 225 ADSs by the Reporting Person on May 20, 2025 pursuant to the Issuer's Employee Share Purchase Plan. F3 · derivative.exercise_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F3 · derivative.expiration_date: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantEmployee Stock Option (right to buy) · Derivative | 124,032 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-25-008554 · form4-03182025_080311.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,032 Underlying: Ordinary Shares · 124,032 shares Expires 2035-03-15 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 20:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantOrdinary Shares | 51,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008554 · form4-03182025_080311.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,338 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · kind: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2025, subject to Reporting Person's continued service on such dates. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 17:47 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare option (right to buy) · Derivative | 82,890 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001415889-24-023794 · form4-09202024_090932.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,890 Underlying: Ordinary Shares · 82,890 shares Expires 2034-09-17 F3 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4 · derivative.exercise_date: One-fourth of the shares vest on the first anniversary of September 18, 2024, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F1 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| September 18, 2024 Filed Sep 20, 2024 17:47 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantOrdinary Shares | 67,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023794 · form4-09202024_090932.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,290 F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2 · shares: Represents restricted stock unit award granted under the Issuer's 2023 Equity Incentive Plan. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 17:04 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionStock option (right to buy) · Derivative | 15,625 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-23-047626 · doc4.xml · derivative · entry 3 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,375 Underlying: Common Stock · 15,625 shares Expires 2032-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 17:04 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | SaleCommon Stock | 15,625 | $6.28 | $98,057.81 |
DisclosureSEC source: 0001209191-23-047626 · doc4.xml · nonDerivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,600 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 17:04 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionCommon Stock | 15,625 | $1.80 | $28,125.00 |
DisclosureSEC source: 0001209191-23-047626 · doc4.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 18:11 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-22-061038 · doc4.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-12-08 F2 · derivative.exercise_date: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 19:49 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001209191-21-064587 · doc4.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2031-11-11 F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on October 11, 2022, and the remaining shares vest in equal monthly installments over the subsequent 36 months. Read SEC document |
| November 12, 2021 Filed Nov 15, 2021 19:49 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-064587 · doc4.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents a restricted stock unit award. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 17:01 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $32.12 | $0.00 |
DisclosureSEC source: 0001628280-21-001177 · wf-form4_161195765095069.xml · derivative · entry 2 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 17:01 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-001177 · wf-form4_161195765095069.xml · nonDerivative · entry 1 Hall Ashley · CIK 0001801842 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · shares: The options vest over a four (4) year period in equal quarterly installments, the first of which will be May 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.